EGFR and non-small cell lung carcinoma: Afatinib, a second-generation EGFR-TKI, is an irreversible ErbB family binder and blocker that inhibits EGFR, HER2, and HER4.[6–8] At present, gefitinib, erlotinib, and afatinib have been approved for EGFR-positive NSCLC patients as a first-line treatment.